Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248940 | 0.89 | WNT3A (0.48) | — | |
| SCHEMBL254331 | 0.87 | HPGD (0.42) | HDAC1 | |
| SCHEMBL14817880 | 0.85 | TBK1 (0.47) | HDAC1HDAC6 | |
| SCHEMBL10257461 | 0.84 | HDAC2 (0.44) | HDAC2HDAC3HDAC1RAF1BRAF | |
| SCHEMBL254330 | 0.83 | HDAC1 (0.47) | HDAC2HDAC3HDAC1 | |
| SCHEMBL1912406 | 0.78 | HDAC2 (0.50) | HDAC2HDAC3HDAC1 | |
| SCHEMBL1329883 | 0.73 | ALDH1A1 (0.64) | HPGDSMAPK8KCNH2 | |
| SCHEMBL246113 | 0.73 | WNT3A (0.57) | — | |
| SCHEMBL252827 | 0.71 | WNT3A (0.50) | — | |
| SCHEMBL247860 | 0.71 | WNT3A (0.55) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2588453-B1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| WO-2012003189-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | IRM LLC (BM) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | HPGDS 1641/4885HDAC2 1820/4885HDAC3 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.